Search results for "Drug carrier"

showing 10 items of 329 documents

Loading profile of topotecan into polyvinyl alcohol microspheres (DC Bead™) over a 7-day period

2011

Purpose: DC Bead™ is successfully used for chemoembolization of various liver cancers. The purpose of this study was todetermine the loading capacity of the semi-synthetic topoisomerase-1 inhibitor topotecan into the DC Bead™ microspheres under static or agitated conditions and to assess the physicochemical stability over a period of 7 days. Methods: Commercially available topotecan hydrochloride powder (Hycamtin®) was reconstituted with water for injection to yield a nominal concentration of 1 mg/mL topotecan. Polyvinyl alcohol (PVA)-based microspheres (DC Bead™, 300–500 µm, 2 mL/vial) were mixed with 4 mL of the reconstituted topotecan solution. Vials were stored light protected at room …

Drug CarriersTopotecan HydrochlorideTime FactorsChromatographyendocrine system diseasesbusiness.industryChemistry PharmaceuticalVialPolyvinyl alcoholMicrospheresMicrospherechemistry.chemical_compoundHplc assayOncologychemistryPolyvinyl AlcoholmedicineLoading ratePharmacology (medical)TopotecanTopotecanbusinessDrug carrierChromatography High Pressure Liquidmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Recombinant cDNA encapsulation in small liposomes with hepatocyte access ability.

1993

Liposomal encapsulation efficiency of a recombinant cDNA was studied by several procedures. We observed that supernatant fraction of ultracentrifuged liposomes prepared by extrusion through polycarbonate filters of 400 nm pore size yielded a very homogeneous suspension of small (50 nm diameter) unilamellar liposomes with highest DNA/lipid ratio and great ability to access to hepatocytes.

Drug CompoundingDNA RecombinantPharmaceutical ScienceBioengineeringBiologyIn Vitro Techniqueslaw.inventionchemistry.chemical_compoundMiceColloid and Surface ChemistrylawComplementary DNAmedicineAnimalsHumansPhysical and Theoretical ChemistryFluoresceinParticle SizeLiposomeDrug CarriersChromatographyParaffin EmbeddingStaining and LabelingOrganic ChemistryFluoresceinsMice Inbred C57BLMicroscopy Electronmedicine.anatomical_structureBiochemistrychemistryLiverHepatocytealpha 1-AntitrypsinLiposomesRecombinant DNAExtrusionParticle sizeDrug carrierFiltrationPlasmidsJournal of microencapsulation
researchProduct

Loading, release and stability of epirubicin-loaded drug-eluting beads.

2015

Purpose The aim of this study was to determine the loading efficiency, physico-chemical stability and release of epirubicin-loaded DC Bead™ (Biocompatibles UK Ltd, a BTG International group company) (bead size 70–150 µm (=DC Bead M1™) and 100–300 µm) after loading with epirubicin solution (2 mg/ml) or reconstituted powder formulation (25 mg/ml) and controlled storage. Methods DC Bead™ were loaded with 76 mg epirubicin solution (Epimedac™, Medac GmbH) or 75 mg epirubicin powder formulation (Farmorubicin™, Pharmacia Pfizer GmbH) per 2 ml of beads. Drug loading efficiency and stability were determined by measuring the epirubicin concentration in the excess solution after predetermined interval…

Drug CompoundingDrug StorageBead030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDrug StabilitymedicinePharmacology (medical)Particle SizeChromatography High Pressure LiquidEpirubicinDrug CarriersChromatographyAntibiotics AntineoplasticDrug eluting beadsElutionbusiness.industrySyringesMicrospheresOncology030220 oncology & carcinogenesisvisual_artDrug releasevisual_art.visual_art_mediumPowdersbusinessEpirubicinmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Synthesis, Characterization, and Study, of New Nanostructured Materials

Drug carrierHalloysite nanotubenanotubeClayHalloysitemetal-based catalystClay mineralEco-compatibleNanospongePollutants removalBioremediationHalloysite; Halloysite nanotubes; Drug carrier; metal-based catalysts; nanotubes; Clay; Clay minerals; Eco-compatible; Nanosponge; Pollutants removal; Bioremediation;
researchProduct

Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications.

2016

To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn (i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100 nm), nanocarrier degradation (1 month to 1 year) and drug…

Drug targetingPolymersPharmaceutical ScienceNanotechnology02 engineering and technologyDocetaxel010402 general chemistry01 natural sciencesMicellechemistry.chemical_compoundCopolymerMicelleschemistry.chemical_classificationAcrylamidesDrug CarriersPolymerDrug release021001 nanoscience & nanotechnology0104 chemical sciencesMolecular WeightDrug LiberationNanomedicineCross-Linking ReagentschemistryTargeted drug deliveryDoxorubicin2023 OA procedureNanomedicinePolymeric micellesTaxoidsCore-crosslinkingNanocarriers0210 nano-technologyDrug carrierEthylene glycolJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium

2013

Current malaria therapeutics demands strategies able to selectively deliver drugs to Plasmodium-infected red blood cells (pRBCs) in order to limit the appearance of parasite resistance. Here, the poly(amidoamines) AGMA1 and ISA23 have been explored for the delivery of antimalarial drugs to pRBCs. AGMA1 has antimalarial activity per se as shown by its inhibition of the in vitro growth of Plasmodium falciparum, with an IC50 of 13.7 μM. Fluorescence-assisted cell sorting data and confocal fluorescence microscopy and transmission electron microscopy images indicate that both polymers exhibit preferential binding to and internalization into pRBCs versus RBCs, and subcellular targeting to the par…

Drug3003PlasmodiumPolyamineErythrocytesPrimaquinemedia_common.quotation_subjectmalariaPharmaceutical ScienceAntimalarialPrimaquinePharmacologyParasitemiatargeted drug deliveryAntimalarialsMiceChloroquineparasitic diseasesPolyaminesmedicineAnimalsInternalizationDrug Carriermedia_commonDrug CarriersMice Inbred BALB CbiologyAnimalPlasmodium falciparumChloroquinePoly(amidoamine)polyamidoaminebiology.organism_classificationnanomedicineErythrocyteTargeted drug deliveryFemalepolymer-drug carrierPlasmodium yoeliimedicine.drug
researchProduct

Core-Shell Arginine-Containing Chitosan Microparticles for Enhanced Transcorneal Permeation of Drugs

2019

Chitosan oligosaccharide (C) was functionalized with L-arginine (A) and short hydrocarbon chains (C-8) to design an amphiphilic copolymer, henceforth CAC(8), leading to microparticles (MPs) consisting of an arginine-decorated hydrophilic shell and inner hydrophobic domains allowing the encapsulation of high amount hydrophobic drugs such as sorafenib tosylate (>10% w/w). L-arginine side chains were selected in order to impart the final MPs enhanced transcorneal penetration properties, thus overcoming the typical biological barriers which hamper the absorption of drugs upon topical ocular administration. The mucoadhesive properties and drug release profile of the CAC(8) MPs (CAC(8)-MPs) were …

Drug3003congenital hereditary and neonatal diseases and abnormalitiesArginineSwinemedia_common.quotation_subjectamphiphilic copolymerPharmaceutical ScienceL-arginineAdministration Ophthalmic02 engineering and technologyArginine030226 pharmacology & pharmacyCorneaChitosan03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineMucoadhesionSide chainAnimalsskin and connective tissue diseasesProtein Kinase Inhibitorsmedia_commonMucin-3microparticlesDrug CarriersMucinnutritional and metabolic diseasesSorafenibPermeation021001 nanoscience & nanotechnologyCombinatorial chemistryBioavailabilityDrug LiberationmicroparticlechemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativoocular administrationchitosan0210 nano-technologymucoadhesion
researchProduct

Coupling of the antiviral agent zidovudine to polyaspartamide and in vitro drug release studies.

1998

A macromolecular prodrug of the known antiretroviral agent zidovudine and alpha, beta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) was synthesized. A succinic spacer was present between the polymer and the drug, and 1,1'-carbonyldiimidazole was used as the coupling agent. In vitro drug release studies at pH 1.1, 5.5 and 7.4 indicated that limited amounts of intact drug were released from the conjugate. At pH 1.1 and 7.4 succinylzidovudine was released, and this was hydrolysed to give free zidovudine. In the presence of alpha-chymotrypsin, zidovudine was released preferentially in comparison with the succinyl derivative. The amounts of released zidovudine and succinylzidovudine were greater …

DrugActive ingredientDrug CarriersChemistryAnti-HIV Agentsmedia_common.quotation_subjectHydrolysisPharmaceutical ScienceProdrugPharmacologyHydrogen-Ion ConcentrationIn Vitro TechniquesIn vitroZidovudinemedicineLiberationChymotrypsinHumansProdrugsDrug carrierPeptidesZidovudinemedia_commonmedicine.drugConjugateJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

2014

Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceAntineoplastic AgentsBioengineeringPharmacologyApplied Microbiology and BiotechnologyCell Line TumormedicineHumansEpidermal growth factor receptorNanostructured lipid carriers Tyrphostin AG-1478 Drug release Hepatocellular carcinoma EGFR inhibitor.media_commonEGFR inhibitorsDrug CarriersNanostructured lipid carriersbiologyChemistryResearchLiver NeoplasmsCorrectionDrug releaseTyrphostinsmedicine.diseaseLipidsTyrphostin AG-1478Molecular medicineIn vitroNanostructuresErbB ReceptorsEGFR inhibitorLiverSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomaDrug deliveryQuinazolinesbiology.proteinMolecular MedicineDrug carrier
researchProduct

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

2018

The oral controlled release (CR) formulations have become more important in recent years. Among them, the polymeric nanoparticles have been thoroughly studied during the last decades, consequently they are extensively employed for a broad range of applications and drugs. The objective of this research was to develop polymeric nanoparticles (NPs) of ibuprofen with poly(lactic-co-glycolic) acid (PLGA) as polymer, and to test their applicability for oral CR formulations development. Different proportions of drug/polymer were employed to develop the ibuprofen NPs and their in vitro release profiles were analysed. The in situ segmental permeability of ibuprofen was tested in Wistar rat and demon…

DrugMaleColonPolymersmedia_common.quotation_subjectPharmaceutical ScienceIbuprofen02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivomedicineAnimalsLactic AcidRats Wistarmedia_commonchemistry.chemical_classificationDrug CarriersChromatographyorganic chemicalstechnology industry and agriculturePolymer021001 nanoscience & nanotechnologyIbuprofenControlled releaseRatsPLGAchemistryIntestinal AbsorptionPermeability (electromagnetism)Delayed-Action PreparationsNanoparticles0210 nano-technologyPolyglycolic Acidmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct